As of 11/30/2022, bebtelovimab is no longer authorized for use in the U.S. due to the rising prevalence of Omicron subvariants, which bebtelovimab is not active against

As of 1/26/2023, Tixagevimab/cilgavimab (Evusheld) is no longer authorized for use in the U.S. due to the rising prevalence of SARS-CoV-2 subvariants and unlikely to be active